Allurion Technologies, Inc. (ALUR) - Net Assets
Based on the latest financial reports, Allurion Technologies, Inc. (ALUR) has net assets worth $-77.91 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.99 Million) and total liabilities ($91.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See ALUR net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-77.91 Million |
| % of Total Assets | -556.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Allurion Technologies, Inc. - Net Assets Trend (2020–2025)
This chart illustrates how Allurion Technologies, Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ALUR stock market capitalisation.
Annual Net Assets for Allurion Technologies, Inc. (2020–2025)
The table below shows the annual net assets of Allurion Technologies, Inc. from 2020 to 2025. Also explore Allurion Technologies, Inc. (ALUR) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-77.19 Million | +1.01% |
| 2024-12-31 | $-77.98 Million | -10.63% |
| 2023-12-31 | $-70.49 Million | -118.13% |
| 2022-12-31 | $-32.31 Million | +5.75% |
| 2021-12-31 | $-34.28 Million | -172985.89% |
| 2020-12-31 | $19.83K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Allurion Technologies, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25095683100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | % |
| Other Comprehensive Income | $5.14 Million | % |
| Other Components | $168.63 Million | % |
| Total Equity | $-77.19 Million | 100.00% |
Allurion Technologies, Inc. Competitors by Market Cap
The table below lists competitors of Allurion Technologies, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CREATIVEF. G.S.A-K ZY-23
F:19F
|
$1.02 Million |
|
Total Helium Ltd
V:TOH
|
$1.02 Million |
|
3 E Network Technology Group Ltd Class A Ordinary Shares
NASDAQ:MASK
|
$1.02 Million |
|
River and Mercantile UK Micro Cap Investment Company Ltd
LSE:RMMC
|
$1.03 Million |
|
General Shopping e Outlets do Brasil S.A.
SA:GSHP3
|
$1.02 Million |
|
Edri-El
TA:EDRL
|
$1.02 Million |
|
Gentlemens Equity S.A.
PA:MLGEQ
|
$1.02 Million |
|
Record PLC
LSE:REC
|
$1.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Allurion Technologies, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -77,978,000 to -77,189,000, a change of 789,000.
- Net loss of 28,755,000 reduced equity.
- New share issuances of 18,970,000 increased equity.
- Other comprehensive income increased equity by 13,510,000.
- Other factors decreased equity by 2,936,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-28.75 Million | -37.25% |
| Share Issuances | $18.97 Million | +24.58% |
| Other Comprehensive Income | $13.51 Million | +17.5% |
| Other Changes | $-2.94 Million | -3.8% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Allurion Technologies, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.07 | $1.02 | x |
| 2021-12-31 | $-119.25 | $1.02 | x |
| 2022-12-31 | $-450.16 | $1.02 | x |
| 2023-12-31 | $-742.87 | $1.02 | x |
| 2024-12-31 | $-520.51 | $1.02 | x |
| 2025-12-31 | $-153.47 | $1.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Allurion Technologies, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -188.80%
- • Asset Turnover: 0.97x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-4.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -26.07% | 0.00% | 0.00x | 16.64x | $-7.15K |
| 2021 | 0.00% | -32.39% | 0.97x | 0.00x | $-8.96 Million |
| 2022 | 0.00% | -58.78% | 1.25x | 0.00x | $-34.51 Million |
| 2023 | 0.00% | -150.76% | 0.75x | 0.00x | $-73.56 Million |
| 2024 | 0.00% | -81.43% | 0.98x | 0.00x | $-18.35 Million |
| 2025 | 0.00% | -188.80% | 0.97x | 0.00x | $-21.04 Million |
Industry Comparison
This section compares Allurion Technologies, Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,453,075,586
- Average return on equity (ROE) among peers: -79.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Allurion Technologies, Inc. (ALUR) | $-77.91 Million | -26.07% | N/A | $1.02 Million |
| Abbott Laboratories (ABT) | $30.72 Billion | 7.71% | 1.19x | $180.30 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $12.40 Million | -202.26% | 2.49x | $10.78 Million |
| Aethlon Medical Inc (AEMD) | $-704.50K | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-879.00K | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $24.31K | -2.84% | 11.78x | $781.40 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $1.53 Million | -361.86% | 1.36x | $4.87 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.01 Million |
| Artivion Inc (AORT) | $328.71 Million | -5.07% | 1.40x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $6.49 Million | -7.93% | 0.31x | $122.16 Million |
About Allurion Technologies, Inc.
Allurion Technologies Inc. focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally. Its Allurion Program platform offers the Allurion Smart Capsule, a swallowable and procedure-less intragastric balloon for weight loss, and access to the Allurion Virtual Care Suite, a digital therapeutic that combines AI-powered remote patient monitoring to… Read more